Today's Date: October 4, 2023
Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception   •   Qwoted Launches Free Networking Tools for PR Industry   •   HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation'   •   Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team   •   Global Clean Energy Reports Largest Camelina Acreage Worldwide   •   Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers   •   Investments and Innovations Drive Expansion of Europe's Elderly Care Medical Devices Market   •   Indie Beauty and Wellness Brand LĀ SOL Collective Expands Product Line with HYDRATE Body Oil   •   ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives   •   Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call   •   Get a Free Google Pixel 8 and Unleash its Full 5G Potential Only at T-Mobile, America’s 5G Leader   •   FINRA Foundation Awards 2023 Ketchum Prize to Long-Time Financial Fraud Fighter Doug Shadel   •   Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid   •   Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs   •   MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX   •   Consumers Energy Continues Clean Energy Transition with Plans for Solar Project at Former Coal Plant Location   •   Grupo EULEN announces Angeles Campoy as the New Chief Executive Officer for USA   •   Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio   •   NAREB's 60-CITY, BLACK WEALTH TOUR BEGINS IN HOUSTON WITH A COMMUNITY WEALTH BUILDING DAY   •   CAMS Wins Ragan CSR, ESG and Diversity Awards
Bookmark and Share

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commerc

EDISON, N.J. , June 01 /Businesswire/ - Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics. As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).

“We have made great progress in the field of TLR7/8 agonists and advanced our molecules to industry leading positions,” said Walter Lau, Ph.D., Chief Executive Officer of Seven and Eight Biopharmaceuticals. “We are delighted to have the Eikon team continue the clinical development and ultimate commercialization of these molecules. Eikon and its highly experienced immuno-oncology team has a proven track record of developing and commercializing industry leading anti-PD-1 therapies, and we believe they will be uniquely positioned to advance our first-in-class TLR7/8 agonists as potential treatments for multiple tumor types.”

“The Seven and Eight Biopharma novel TLR7/8 agonists have, in Phase I trials, shown an acceptable safety profile in over 150 patients treated in mono- or in combination with anti-PD-(L)1 therapy,” said Robert H.I. Andtbacka, M.D., C.M., Chief Medical Officer of Seven and Eight Biopharmaceuticals. “In addition, encouraging clinical responses have been seen in both mono- and combination therapy in multiple heavily pre-treated tumor types. We are excited to see the development of these novel TLR7/8 agonist continue under Eikon’s leadership.”

The exclusive licensing agreement also includes development of novel Toll-like receptor ligand antibody conjugation (TLAC) molecules. "Over the years, Seven and Eight Biopharma has built not only TLR7/8 agonist programs from the ground up but also an innovative TLAC platform, and we are glad to see the continued development of these promising molecules” said Lixin Li, M.D., Ph.D., Chief Technical Officer of Seven and Eight Biopharmaceuticals.

About Seven and Eight Biopharma

Seven and Eight Biopharmaceuticals Inc. is an Edison, New Jersey based, clinical stage biotechnology company focused on the development and commercialization of novel immunotherapies for cancer. The company specializes in TLR7/8 programs to treat cancer and has built a comprehensive global intellectual property portfolio in the category of toll-like receptor modulators. Managed by a seasoned team of professionals, the company is progressing a proprietary pipeline of cancer therapeutics in the U.S., with novel TLR7/8 agonists being evaluated in Phase I and Phase II clinical trials in monotherapy and in combination with both anti-PD-1 and anti-PD-L1 monoclonal antibodies.

For more information, please visit

STORY TAGS: Contract/Agreement, Product/Service, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, United States, North America, New Jersey,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News